# Obicetrapib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/obicetrapib

> The next catalyst for obicetrapib, sponsored by NewAmsterdam Pharma Co N.V. (NAMS), is its primary completion, November 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | obicetrapib |
| Codes |  |
| Sponsor | NewAmsterdam Pharma Co N.V. (NAMS) https://sec-api.dev/companies/nams/catalysts |
| Indications | hefh, ascvd or ascvd risk equivalents, hefh, ascvd or ascvd risk equivalent patients, type 2 diabetes or metabolic syndrome, established atherosclerotic cardiovascular disease, Lipidemia, [Dyslipidemias](https://sec-api.dev/indications/dyslipidemias), [Atherosclerotic Cardiovascular Disease](https://sec-api.dev/indications/atherosclerotic-cardiovascular-disease), [Antioxidant Absorption](https://sec-api.dev/indications/antioxidant-absorption) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar 2022: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-02-26, last confirmed 2025-02-26.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-027336): "The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE." https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/nams-ex99_1.htm

### Jul 2024: topline data readout

- Status: completed, met. Date confidence: month.
- First seen 2025-02-26, last confirmed 2026-02-18.
- SEC Form 10-K (accession 0001193125-26-056029): "We announced topline results for BROOKLYN in July 2024 and for BROADWAY in December 2024, both of which met the primary endpoint for the study with safety and tolerability comparable to placebo." https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- SEC Form 10-K (accession 0000950170-25-027339): "We announced topline results for BROOKLYN in July 2024 and for BROADWAY in December 2024, both of which met the primary endpoint for the study with safety and tolerability comparable to placebo." https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm

### Nov 2024: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: HeFH, ASCVD or ASCVD risk equivalents.
- First seen 2025-02-26, last confirmed 2026-02-18.
- SEC Form 10-K (accession 0001193125-26-056029): "Based on the results of this pilot bioequivalence trial and the data and learnings from our ROSE2 trial, we selected a formulation for an FDC tablet of obicetrapib and ezetimibe and initiated TANDEM, a Phase 3 pivotal trial, to evaluate 10 mg obicetrapib and 10 mg ezetimibe as an FDC used as an adjunct to diet and maximally tolerated lipid-lowering therapies to potentially enhance LDL-C lowering in patients with HeFH, ASCVD or ASCVD risk equivalents, in the first quarter of 2024 and announced topline data in November 2024." https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- SEC Form 10-K (accession 0001193125-26-056029): "Based on the results of this pilot bioequivalence trial and the data and learnings from our ROSE2 trial, we have selected a formulation for an FDC tablet of obicetrapib and ezetimibe and initiated TANDEM, a Phase 3 pivotal trial, to evaluate 10 mg obicetrapib and 10 mg ezetimibe as an FDC used as an adjunct to diet and maximally tolerated lipid-lowering therapies to potentially enhance LDL-lowering in patients with HeFH, ASCVD or ASCVD risk equivalent patients, in the first quarter of 2024 and released topline data in November 2024." https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- SEC Form 10-K (accession 0000950170-25-027339): "Based on the results of this pilot bioequivalence trial and the data and learnings from our ROSE2 trial, we selected a formulation for a fixed-dose combination tablet of obicetrapib and ezetimibe and initiated TANDEM, a Phase 3 pivotal trial, to evaluate 10 mg obicetrapib and 10 mg ezetimibe as a fixed-dose combination used as an adjunct to diet and maximally tolerated lipid-lowering therapies to potentially enhance LDL-C lowering in patients with HeFH, ASCVD or ASCVD risk equivalents, in the first quarter of 2024 and announced topline data in November 2024." https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm

### December 10, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: established atherosclerotic cardiovascular disease.
- First seen 2024-12-10, last confirmed 2025-02-26.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-273959): "with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced positive topline data from the Companys Phase 3 BROADWAY clinical trial (NCT05142722) evaluating obicetrapib in adult patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy." https://www.sec.gov/Archives/edgar/data/1936258/000119312524273959/d910195dex991.htm
- SEC Form 10-K (accession 0000950170-25-027339): "On December 10, 2024, we announced positive topline data from our Phase 3 BROADWAY clinical trial." https://www.sec.gov/Archives/edgar/data/1936258/000095017025027339/nams-20241231.htm

### Aug 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-02-18, last confirmed 2026-02-18.
- SEC Form 10-K (accession 0001193125-26-056029): "Other than our submission to the EMA and the EMA's acceptance of MAAs for review for obicetrapib in August 2025, we have not previously submitted an NDA, an MAA or any similar drug approval filing to the FDA, the EMA or any comparable regulatory authority for any product candidate, and we cannot be certain that obicetrapib will be successful in clinical trials or receive regulatory approval." https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Antioxidant Absorption.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06982508 (Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT06982508

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Antioxidant Absorption.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06982508 (Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT06982508

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atherosclerotic Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05202509 (Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT05202509

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atherosclerotic Cardiovascular Disease.
- First seen 2026-01-09, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05202509 (Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT05202509
- Press release filed with the SEC (EX-99) (accession 0001193125-26-056020): "In December 2025, we initiated the RUBENS trial, which will evaluate obicetrapib alone and in combination with ezetimibe in patients with type 2 diabetes or metabolic syndrome that require additional lowering of LDL-C despite treatment with available therapy, with topline data expected by year-end 2026." https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/nams-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-056029): "The study is expected to enroll approximately 300 patients, with topline data expected by the end of 2026." https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-333827): "The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026." https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-333827): "the Company's expectations for total enrollment figures for and topline data from the RUBENS trial by year-end 2026" https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210283): "The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026." https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/nams-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210283): "expectations for total enrollment figures for and topline data from the RUBENS trial by year-end 2026" https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/nams-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-056020): "The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026." https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/nams-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-008300): "We expect topline results from the trial by the end of 2026."" https://www.sec.gov/Archives/edgar/data/1936258/000119312526008300/nams-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-008300): "The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026." https://www.sec.gov/Archives/edgar/data/1936258/000119312526008300/nams-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-446228): "In August 2026, the trial completed enrollment of 347 patients, and we expect to report topline data from RUBENS around year end 2026." https://www.sec.gov/Archives/edgar/data/1936258/000119312526446228/nams-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-333824): "The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026." https://www.sec.gov/Archives/edgar/data/1936258/000119312526333824/nams-20260630.htm

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Dyslipidemias.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06496243 (Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT06496243

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Dyslipidemias.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06496243 (Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT06496243

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06305559 (A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT06305559

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06305559 (A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT06305559

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07219602 (A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT07219602

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07219602 (A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT07219602

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Preclinical Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07794670 (Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT07794670

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Preclinical Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07794670 (Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor NewAmsterdam Pharma." https://clinicaltrials.gov/study/NCT07794670

## Same indication

- [Aro-apoc3](https://sec-api.dev/pdufa/aro-apoc3) (ARWR)
- [Leqvio (inclisiran sodium)](https://sec-api.dev/pdufa/inclisiran) (NVS)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Olpasiran](https://sec-api.dev/pdufa/olpasiran) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/obicetrapib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Obicetrapib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/obicetrapib

```bibtex
@misc{secapidev_pdufa_obicetrapib_20261116,
  title        = {Obicetrapib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/obicetrapib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_obicetrapib_20261116","title":"Obicetrapib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/obicetrapib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
